ESC 2023 Dyslipidemia: New LDL-C Targets & Non-Statin Rx

Abstract

The European Society of Cardiology (ESC) 2023 Guidelines for the Management of Dyslipidaemias represent a significant intensification of therapeutic goals, particularly for patients at very high cardiovascular risk. 

These updates reinforce the fundamental role of low-density lipoprotein cholesterol (LDL-C) reduction as the primary target for preventing atherosclerotic cardiovascular disease (ASCVD). 

Key revisions include further lowering the LDL-C treatment goal to less than 1.4 mmol/L (<55 mg/dL) combined with a ≥ 50% reduction from baseline for very high-risk individuals. The guidelines provide reinforced, evidence-based recommendations for integrating non-statin therapies—specifically PCSK9 inhibitors, inclisiran, and bempedoic acid—into the treatment paradigm when maximal tolerated statin therapy fails to achieve risk-specific targets. 

This review summarizes the crucial updates, outlines the refined risk stratification, and contextualizes the clinical data supporting the contemporary use of these novel agents in high-risk cardiology practice.

Introduction: The Evolving Landscape of Lipid Management

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality across Europe and globally, placing a substantial burden on healthcare systems. 

The causality of low-density lipoprotein cholesterol (LDL-C) in the pathogenesis of atherosclerosis is unequivocal, supported by genetic, epidemiological, and vast randomized controlled trial (RCT) evidence. Consequently, lipid modification to reduce LDL-C is the cornerstone of both primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD).

The European Society of Cardiology (ESC) 2023 Guidelines represent a focused update building upon the established principle that “lower is better” for LDL-C. This iteration of the guidelines reflects the maturation of evidence from major clinical trials involving both established and novel non-statin lipid-lowering therapies (LLTs). 

The update emphasizes a more aggressive, risk-driven approach to goal attainment, especially in the highest-risk populations who stand to gain the most absolute risk reduction.

Key shifts in the updated guidelines include:

• Intensified LDL-C Targets: The reinforcement and further lowering of treatment goals for very high-risk patients.
  
  
• Integration of Novel Agents: Formal incorporation of evidence from dedicated cardiovascular outcomes trials (CVOTs) for agents beyond statins and ezetimibe, such as PCSK9 inhibitors (PCSK9i), inclisiran, and bempedoic acid, defining their place in combination therapy and for managing statin intolerance.
  
  

This critical summary aims to elucidate these pivotal updates, focusing on the rationale behind the stringent new LDL-C goals and the evidence-based integration of advanced non-statin pharmacotherapy into contemporary clinical practice.

Updated LDL-C Targets and Risk Stratification

The core message of the ESC 2023 Dyslipidaemia Guidelines is a risk-driven approach that mandates intensive low-density lipoprotein cholesterol (LDL-C) lowering, particularly in the highest-risk cohorts. The stratification of cardiovascular risk remains central to determining the appropriate LDL-C treatment goal and the intensity of pharmacologic intervention. Risk is defined based on the presence of established atherosclerotic cardiovascular disease (ASCVD), high-risk conditions (e.g., familial hypercholesterolemia), or calculated risk scores (e.g., SCORE2/SCORE2-OP).

Very High-Risk Patients

This cohort is targeted for the most aggressive therapeutic strategy, reflecting the profound lifetime risk of recurrent major adverse cardiovascular events (MACE).

Definition: Very high risk is defined by any one of the following criteria:

• Established ASCVD: Documented clinical disease (e.g., prior myocardial infarction, acute coronary syndrome, coronary revascularization, ischemic stroke, peripheral arterial disease).
  
  
• Severe Comorbidities:
  • Type 2 Diabetes Mellitus (T2DM) with target organ damage or ≥ 3 major risk factors, or early-onset T1DM of long duration (>20 years).
    
    
  • Chronic Kidney Disease (CKD) with severely reduced GFR (<30 mL/min/1.73 m²).
    
    
  • Familial Hypercholesterolemia (FH) with established ASCVD or another major risk factor.
    
    
• Calculated Risk: SCORE2 ≥ 7.5% (for fatal and non-fatal 10-year risk of MACE) or SCORE2-OP ≥ 7.5% (for individuals ≥ 65 years old).
  
  

LDL-C Target: For very high-risk patients, the guideline establishes a dual therapeutic goal:

1. An LDL-C level of <1.4 mmol/L (<55 mg/dL).
   
   
2. A minimum ≥ 50% reduction from baseline LDL-C level.
   
   

These targets are classified as a Class I, Level A recommendation, underscoring the high-level evidence from trials that consistently demonstrate incremental benefit with intensive lowering.

High-Risk Patients

This group also requires significant lipid management to mitigate substantial future risk.

Definition: High risk is defined by any one of the following:

• Marked Single Risk Factor: Severely elevated single risk factor, such as FH without other major risk factors, or a severely elevated LDL-C (>4.9 mmol/L or >190 mg/dL).
  
  
• Moderate Comorbidities:
  • T2DM without target organ damage or other major risk factors.
    
    
  • CKD with moderately reduced GFR (30-59 mL/min/1.73 m²).
    
    
• Calculated Risk: SCORE2 ≥ 5% and <7.5% (or SCORE2-OP ≥ 7.5% and <10% for those ≥ 65 years old).
  
  

LDL-C Target: The target for high-risk patients is:

1. An LDL-C level of <1.8 mmol/L (<70 mg/dL).
   
   
2. A minimum ≥ 50% reduction from baseline LDL-C level.
   
   

Therapeutic Goals

The commitment to achieving a dual goal (absolute target and relative reduction) reinforces the need for effective, high-intensity pharmacotherapy from the outset.

Intensified Pharmacologic Management: Non-Statin Therapies

The ESC 2023 guidelines firmly establish the sequential, step-wise approach to achieving the stringent LDL-C targets, often requiring combination therapy. The therapeutic cascade begins with high-intensity statin therapy, escalating to the addition of non-statin agents based on residual LDL-C levels and patient risk.

Statin Therapy

Statins (HMG-CoA reductase inhibitors) remain the Class I, Level A first-line intervention for all risk categories due to their proven efficacy, safety profile, and cardiovascular outcomes data. The strategy mandates the use of the maximally tolerated dose of a potent statin (e.g., rosuvastatin or atorvastatin) to achieve the risk-specific LDL-C target and the ≥ 50% reduction from baseline.

Ezetimibe

Ezetimibe, a cholesterol absorption inhibitor, is the recommended first-line add-on agent when the LDL-C target is not met on maximal tolerated statin therapy. This recommendation is supported by the IMPROVE-IT trial, which demonstrated that the addition of ezetimibe to simvastatin provided incremental reductions in LDL-C (by approx 15-20%) and achieved a significant relative reduction in major atherosclerotic events. Ezetimibe is well-tolerated and offers a crucial non-statin mechanism for reaching target levels, particularly in very high-risk patients.

PCSK9 Inhibitors (PCSK9i)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (e.g., alirocumab, evolocumab) are monoclonal antibodies that prevent the degradation of the hepatic LDL receptor, significantly enhancing the clearance of circulating LDL-C.

Place in Therapy: PCSK9i are reserved for very high-risk patients who, despite maximal tolerated statin therapy and ezetimibe, fail to meet their LDL-C target (<1.4 mmol/L or <55 mg/dL).

Clinical Evidence:

• FOURIER Trial (Evolocumab): Evolocumab reduced the risk of the primary composite endpoint by 15% (Hazard Ratio (HR), 0.85; 95% CI, 0.79-0.92) in patients with stable ASCVD on statin therapy.
  
  
• ODYSSEY OUTCOMES Trial (Alirocumab): Alirocumab reduced the risk of the primary composite endpoint by 15% (HR, 0.85; 95% CI, 0.78-0.93) in patients with recent Acute Coronary Syndrome (ACS).
  
  

These trials consistently showed that PCSK9i provide an additional 50-60% LDL-C reduction and translate to a sustained reduction in cardiovascular events.

Inclisiran

Inclisiran is a novel small-interfering RNA (siRNA) therapy that targets the mRNA for the PCSK9 protein in the liver, leading to a profound and durable reduction in PCSK9 synthesis. Its primary advantage is the subcutaneous twice-yearly dosing schedule.

Place in Therapy: Inclisiran is a treatment option for secondary prevention in ASCVD patients and for primary prevention in individuals with high-risk conditions like Familial Hypercholesterolemia (FH), particularly where adherence to other therapies is a concern.

Clinical Evidence: The ORION Phase 3 trials demonstrated consistent LDL-C reductions of approximately 50% from baseline in patients with ASCVD or FH.

Bempedoic Acid

Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver, offering a non-statin option, particularly for patients with statin intolerance.

Place in Therapy: It is recommended as an add-on therapy for patients with ASCVD or high-risk conditions who require further LDL-C lowering but cannot tolerate statins, or as a combination therapy when statins/ezetimibe are insufficient.

Clinical Evidence: The CLEAR OUTCOMES trial, which included statin-intolerant, high-risk patients, demonstrated that bempedoic acid reduced LDL-C by 21.1 percentage points compared to placebo and achieved a statistically significant 13% relative risk reduction in MACE-4 (HR, 0.87; 95% CI, 0.79-0.96).

Management of Specific Populations

The ESC 2023 Guidelines provide tailored recommendations for managing dyslipidaemia in specific cohorts.

Statin Intolerance

Statin intolerance requires a structured diagnostic and management approach:

1. Re-challenge and Dose Adjustment: Confirmed SAMS should prompt re-challenge with a different statin or intermittent dosing.
   
   
2. Non-Statin Alternatives: If confirmed intolerance to all tolerable statins exists, therapy shifts to non-statin agents:
   
   
   • First-line Non-statin: Ezetimibe.
     
     
   • Second-line Non-statin (High-Risk): Bempedoic acid (substantiated by CLEAR OUTCOMES).
     
     
   • Third-line Non-statin (Very High-Risk): PCSK9 inhibitors (PCSK9i) or inclisiran for those who still do not reach the goal.
     
     

Familial Hypercholesterolemia (FH)

Familial Hypercholesterolemia (FH) is a genetic disorder requiring aggressive, lifelong therapy (Class I recommendation).

• Targets: FH patients without ASCVD are high-risk (<1.8 mmol/L or <70 mg/dL). Those with FH and ASCVD are very high-risk (<1.4 mmol/L or <55 mg/dL).
  
  
• Therapy: Treatment typically begins with high-intensity statins combined with ezetimibe.
  
  
• Intensification: Due to high baseline LDL-C, most FH patients will require the early addition of a PCSK9i or inclisiran to achieve risk-specific targets.
  
  

Emerging Therapies & Research Directions

Ongoing research targets pathways beyond the LDL receptor axis to address residual cardiovascular risk.

Targeting Lipoprotein(a) [Lp(a)]

Elevated Lp(a) is an independent, causal risk factor for ASCVD. Current investigational therapies, such as Pelacarsen (ASO) and Lepodisiran (siRNA), have demonstrated profound reductions in Lp(a) (often >80%). Their definitive role awaits the results of large-scale cardiovascular outcomes trials, such as the Lp(a) HORIZON trial.

Targeting Angiopoietin-Like Protein 3 (ANGPTL3)

Inhibition of ANGPTL3 (e.g., with Evinacumab for HoFH) offers a mechanism independent of the LDL receptor, proving useful for refractory dyslipidaemia with high LDL-C, VLDL, and triglycerides.

Other Novel Targets and Delivery Methods

Research continues on Oral PCSK9 Inhibitors (e.g., Enlicitide) and CETP Inhibitors (e.g., Obicetrapib), aiming to provide convenient yet potent LDL-C reduction options.

Clinical Practice Summary & Key Takeaways

The ESC 2023 Dyslipidaemia Guidelines mandate a paradigm shift towards more aggressive LDL-C lowering, particularly for patients at the highest risk. The clinical implementation of these targets necessitates the early and strategic use of combination pharmacotherapy to meet the stringent dual goals.

Practice Highlights: Major Class I Recommendations

• Risk Stratification is Key: All therapeutic decisions must be guided by accurate, updated cardiovascular risk stratification (Very High, High, Moderate, Low).
  
  
• Dual Goal Standard: For very high-risk patients, the target is an LDL-C level <1.4 mmol/L (<55 mg/dL) AND a ≥ 50% reduction from baseline.
  
  
• Statin First: Maximize the use of high-intensity statin therapy at the maximally tolerated dose before adding other agents.
  
  
• Sequential Combination: If the LDL-C target is not met, the recommended therapeutic sequence is: Statin →  Add Ezetimibe →  Add a PCSK9 inhibitor (or Inclisiran) or Bempedoic acid.
  
  

Table 1: ESC 2023 LDL-C Goals by Risk Category